文献速递临床微生物质量管理与危急值

三种革兰阴性菌血症快速药敏系统的头对头比较:VITEK REVEAL、VITEK 2-RAST与EUCAST纸片扩散法

Improving time-to-result: head-to-head comparison of three rapid AST systems for Gram-negative bacteremia, including the newly developed VITEK REVEAL.
PubMed 文献 · J Clin Microbiol · 2025-10-09

该研究前瞻性收集220份革兰阴性菌阳性血培养,对VITEK REVEAL、直接血培养VITEK 2(VITEK 2-RAST)和EUCAST纸片扩散法(DD-RAST)三种快速药敏系统进行头对头比较,以微量肉汤稀释法为参考。VITEK REVEAL和VITEK 2-RAST分别显示97.1%和96.2%的基本一致率,三种方法分类一致率均≥98.2%,极重大误差率≤1.8%。VITEK REVEAL平均报告时间(6小时32分钟)显著短于VITEK 2-RAST(13小时51分钟)和DD-RAST(固定8小时)。

要点

  • VITEK REVEAL基本一致率97.1%、分类一致率98.3%,覆盖3603个菌-药组合。
  • 三种快速药敏系统分类一致率均≥98.2%,极重大误差率≤1.8%。
  • VITEK REVEAL平均报告时间6小时32分钟,显著短于其他两种方法。

核心结论

  • 三种快速药敏系统直接用于革兰阴性菌阳性血培养均表现高分类一致率(≥98.2%)和低极重大误差率(≤1.8%)。
  • VITEK REVEAL在保持高准确性的同时报告时间显著最短,尤其对耐药菌和β-内酰胺/β-内酰胺酶抑制剂复方抗生素。

研究设计与样本

  • 前瞻性收集220份革兰阴性菌阳性血培养,涵盖18个菌种(含肠杆菌目、鲍曼不动杆菌和铜绿假单胞菌),测试25种抗生素(含4种新一代β-内酰胺/β-内酰胺酶抑制剂复方)。
  • 以微量肉汤稀释法为参考,比较VITEK REVEAL、直接血培养VITEK 2(VITEK 2-RAST)和EUCAST纸片扩散法(DD-RAST)三种快速药敏系统。

主要发现

  • VITEK REVEAL在3603个菌-药组合中基本一致率97.1%、偏倚-7.7、分类一致率98.3%;VITEK 2-RAST在3941个组合中基本一致率96.2%、偏倚-10.4、分类一致率98.4%。
  • DD-RAST在2388个组合中分类一致率98.2%。
  • 在164份三种方法均测试的阳性血培养中,VITEK REVEAL和VITEK 2-RAST基本一致率分别为97.5%和96.3%,偏倚分别为-7.1和-6.9。
  • 三种方法分类一致率均≥98.2%,极重大误差率≤1.8%。
  • VITEK REVEAL平均报告时间6小时32分钟,显著短于VITEK 2-RAST的13小时51分钟和DD-RAST的固定8小时;耐药菌(含BL/BLI抗生素)报告更快,鲍曼不动杆菌报告时间最短且未观察到极重大误差。

关键数值与推荐

  • VITEK REVEAL:基本一致率97.1%,偏倚-7.7,分类一致率98.3%(3603个菌-药组合)。
  • VITEK 2-RAST:基本一致率96.2%,偏倚-10.4,分类一致率98.4%(3941个菌-药组合)。
  • DD-RAST:分类一致率98.2%(2388个菌-药组合)。
  • 三种方法分类一致率≥98.2%,极重大误差率≤1.8%。
  • VITEK REVEAL平均报告时间6小时32分钟,VITEK 2-RAST 13小时51分钟,DD-RAST固定8小时。

临床怎么用

  • 可考虑将快速药敏系统直接用于革兰阴性菌阳性血培养,以缩短报告时间并支持抗菌药物管理。
  • VITEK REVEAL因报告时间短且准确性高,尤其适用于耐药菌和BL/BLI抗生素的药敏检测。
  • 实际应用需评估系统与常规工作流程的整合程度,因其直接影响报告时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Early antimicrobial susceptibility testing (AST) in Gram-negative (GN) bloodstream infections is critical to guide appropriate therapy. This study evaluated three rapid AST (RAST) systems-VITEK REVEAL, direct-from-blood-culture VITEK 2 (VITEK 2-RAST), and EUCAST disk diffusion (DD-RAST)-using 220 prospectively collected GN-positive blood cultures (GN-PBCs). A total of 18 GN species were tested, including Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa, against 25 antibiotics, four of which were next-generation β-lactam/β-lactamase inhibitor (BL/BLI) antibiotics. Reference broth microdilution was used for comparison. The VITEK REVEAL assay showed 97.1% essential agreement (EA), -7.7 bias, and 98.3% categorical agreement (CA) across 3,603 organism/antibiotic combinations. The VITEK 2-RAST assay showed 96.2% EA, -10.4 bias, and 98.4% CA across 3,941 combinations. The DD-RAST assay showed 98.2% CA across 2,388 combinations. Among 164 GN-PBCs tested with all three assays, EA rates were 97.5% for VITEK REVEAL and 96.3% for VITEK 2-RAST, with bias values of -7.1 and -6.9, respectively. Across all three assays, the CA rate was ≥98.2%, and very major error (VME) rates were ≤1.8%. Mean time-to-result (TTR) was significantly shorter with VITEK REVEAL (6 h 32 min) compared to VITEK 2-RAST (13 h 51 min) and the fixed 8 h of DD-RAST. In resistant organisms, VITEK REVEAL produced significantly faster results than in susceptible or intermediate ones, including BL/BLI antibiotics. A. baumannii yielded the shortest TTR, with no observed VME. These results support the use of RAST directly on GN-PBCs, with VITEK REVEAL emerging as a particularly promising option for rapid and accurate testing. IMPORTANCE: This study is the first to conduct a direct comparison of three rapid antimicrobial susceptibility testing (RAST) systems-VITEK REVEAL, VITEK 2-RAST, and DD-RAST-on a large, prospectively collected cohort of Gram-negative-positive blood cultures (GN-PBCs). The data offer valuable insights for laboratories evaluating RAST implementation, especially in EUCAST-based contexts. Among the systems tested, VITEK REVEAL stood out for its combination of rapid turnaround and high accuracy, including for antibiotic-resistant organisms and β-lactam/β-lactamase inhibitor (BL/BLI) antibiotics. These findings underscore the potential of RAST systems to deliver timely and reliable susceptibility results directly from GN-PBCs, thereby supporting more effective antimicrobial stewardship and clinical decision-making. However, the real-world impact will also depend on how well these systems integrate into routine workflows, as seamless implementation can directly affect time-to-result (TTR)-an essential element in optimizing the management of GN-bloodstream infection (BSI).

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Squitieri D, Menchinelli G, Magrì C, et al. Improving time-to-result: head-to-head comparison of three rapid AST systems for Gram-negative bacteremia, including the newly developed VITEK REVEAL. J Clin Microbiol. 2025. PMID: 41065398. doi:10.1128/jcm.01050-25

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。